Sirolimus rescue therapy for refractory rejection in renal transplantation

Transplantation

Volumn 71, Issue 11, 2001, Pages 1579-1584

  Hong, Johnny C ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; ARTICLE; BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG PULSE THERAPY; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0035876088     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200106150-00016     Document Type: Article

References (26)

1. Analysis of the UNOS scientific renal transplant registry at three years: Early events affecting transplant success
2. Immunologic factors: The major risk for decreased long-term renal allograft survival
3. Tacrolimus for rescue of refractory renal allograft rejection
4. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection: A report of the Tacrolimus Kidney Transplantation Rescue Study Group
5. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection
6. Sirolimus (Rapamune, rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: A phase III U.S. multicenter trial
7. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
8. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin
9. Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats
10. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin
11. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates
12. Case report: Sirolimus rescue therapy for refractory renal allograftrejection
13. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
14. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation co-administration on the pharmacokinetics of each agent
15. Established immunosuppressive drugs: Clinical and toxic effects
16. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection
17. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
18. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
19. Conversion from liquid to solid sirolimus formulations in stable renal allograft transplant recipients
20. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
21. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro
22. Synergistic mechanisms by which sirolimus and cyclosporine inhibit rat heart and kidney all allograft rejection
23. Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats
24. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management
25. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease
26. Studies in experimental models of chronic rejection: Use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis